TriangleHEALTH PROFESSIONAL · SOURCE READING
Bevacizumab
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Bevacizumab is a humanized, anti–vascular endothelial growth factor monoclonal antibody.
Evidence (bevacizumab):
A phase II study included 16 assessable patients with KS and HIV. Patients received bevacizumab intravenously (IV) on days 1 and 8 and then every 3 weeks.[21]
Source links and citations
A phase II study included 16 assessable patients with KS and HIV. Patients received bevacizumab intravenously (IV) on days 1 and 8 and then every 3 weeks.[21]
There was a response in 5 of 16 patients. These patients had not improved after prior antiretroviral therapy and chemotherapy.[21][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice